Evaluation: body fat, body weight, lipid markers
WADA names AOD-9604 explicitly under S2.2.3 (Growth hormone, its analogs and fragments) on the 2026 Prohibited List, alongside the unmodified hGH 176-191 fragment
While direct receptor binding affinity remains an area of ongoing investigation, experimental evidence indicates that AOD 9604 enhances 3-adrenergic receptor expression and signaling capacity in adipose tissue models
[30] At the injection site, its possible to have some redness, swelling, or irritation
Most of our weight loss treatments are well-tolerated, but some patients may experience mild side effects such as nausea, headaches, or injection site discomfort
Get expert care from top-rated providers Find the right provider for your needs select your state to find expert care near you.